Safety and efficacy of the therapy with <scp>CD4</scp> + <scp>CD25highCD127</scp> ‐T regulatory cells: When paediatric patient becomes adult
We confirmed the long-term safety and efficacy of the therapy. Due to the superior efficacy profile, the combined treatment with Tregs and antiCD20 antibody should be considered as a routine therapy for recent-onset type 1 diabetes patients.
Authors
- Arkadiusz Michalak (ORCID: https://orcid.org/0000-0002-6088-9636)
- Bartosz Trzeciak (ORCID: https://orcid.org/0000-0002-8316-9826)
- Małgorzata Myśliwiec (ORCID: https://orcid.org/0000-0002-1533-8544)
- Jacek Burzyński
- Katarzyna Stefańska (ORCID: https://orcid.org/0000-0002-8612-9344)
- Anna Wołoszyn‐Durkiewicz (ORCID: https://orcid.org/0000-0003-2099-9707)
- Paulina Glasner (ORCID: https://orcid.org/0000-0002-0913-9530)
- Matylda Hennig (ORCID: https://orcid.org/0000-0001-5247-7490)
- Piotr Gutknecht (ORCID: https://orcid.org/0000-0003-0227-3128)
- Dorota Iwaszkiewicz‐Grześ (ORCID: https://orcid.org/0000-0003-1177-1874)
- Magdalena Piotrowska (ORCID: https://orcid.org/0000-0002-1630-3773)
- Anna Alska
- Piotr Trzonkowski
- Mateusz Gliwiński
- Janusz Siebert (ORCID: https://orcid.org/0000-0002-7254-271X)
- Marta Bandura
- Julia Schoenhoff
- Milena Dybowska
- Marcin Hellmann
Institutions
- Medical University of Lodz (PL)
- Gdańsk Medical University (PL)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1111/dom.70330
- Citations
- 1
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.82